DV
Dividend Vision

TARA — Protara Therapeutics Inc

Protara Therapeutics Inc (TARA)

Total return is -99.0% over the past 11.8 years, 489.5 points behind SPY at 390.5%. Its deepest 1-year drawdown was 51.7%.

Protara Therapeutics is a clinical-stage biopharmaceutical company developing transformative therapies for cancer and rare diseases, with its lead program being TARA-002, an investigational cell therapy in Phase II trials for non-muscle invasive bladder cancer and lymphatic malformations, along with an intravenous choline chloride program for parenteral nutrition patients. The company does not currently distribute dividends. This stock appeals primarily to investors with risk tolerance for early-stage biotech development and those seeking exposure to innovative cell therapy approaches rather than current income generation.

TARA key facts

Asset type
Stock
Asset class
Equity
Inception date
10/22/2014
Last close
$3.97
Market cap
$228,751,248
Average volume
333200.0
Payment date
01/10/2020
Beta
1.479
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.35